Page 4 - Amanda Sheldon News Today

WESTLAKE VILLAGE, Calif., April 25, 2023 -- Arcutis Biotherapeutics, Inc. , an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in... | April 25, 2023

FDA has set a target action date of December 16, 2023NDA supported by positive efficacy and safety data from the Phase 2 and pivotal Phase 3 trials of roflumilast foamIf approved, roflumilast foam... | April 18, 2023

New INTEGUMENT-1 and INTEGUMENT-2 data show a rapid and significant reduction in itch as early as 24 hours after the first application of roflumilast cream...

12.12.2022 - Study met the primary endpoint and key secondary endpoints, consistent with positive topline results from the INTEGUMENT-1 trial released in NovemberFor the primary endpoint, 28.9% of individuals treated with roflumilast cream 0.15% achieved ...

25.10.2022 - WESTLAKE VILLAGE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) - Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a ...

Study met both co-primary endpoints and all secondary endpointsAt week eight, 67.3% of individuals treated with roflumilast foam achieved Scalp-Investigator Global Assessment Success compared to... | September 26, 2022

Study met its primary endpoint with 80% of individuals treated with roflumilast foam achieving Investigator Global Assessment Success compared to 59% of patients treated with vehicle More than 60% of... | September 9, 2022

Felonies

WESTLAKE VILLAGE, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on...

/PRNewswire/ -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) today announced the launch of an educational campaign designed to raise awareness about the...